Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
Related Tickers: MNPR
TL;DR
Monopar Therapeutics filed an 8-K on 9/12/24. Details to follow.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on September 12, 2024, reporting an event under Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the event, but it confirms the company's reporting status.
Why It Matters
This 8-K filing indicates a material event has occurred for Monopar Therapeutics, requiring disclosure to the public. Investors should review the full filing for details.
Risk Assessment
Risk Level: low — The filing is a standard 8-K current report and does not, in itself, indicate any specific negative events or financial distress.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- September 12, 2024 (date) — Date of earliest event reported
- Regulation FD Disclosure (event) — Item Information
- Financial Statements and Exhibits (document) — Item Information
FAQ
What is the specific event being disclosed in this 8-K filing?
The filing indicates 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as items of disclosure, but the specific event details are not provided in the excerpt.
When was the earliest event reported in this filing?
The earliest event reported was on September 12, 2024.
What is the exact name of the registrant?
The exact name of the registrant is Monopar Therapeutics Inc.
In which state was Monopar Therapeutics Inc. incorporated?
Monopar Therapeutics Inc. was incorporated in Delaware.
What is the principal executive office address for Monopar Therapeutics Inc.?
The principal executive offices are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-09-12 08:00:10
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240911_8k.htm (8-K) — 25KB
- ex_723316.htm (EX-99.1) — 13KB
- f1.jpg (GRAPHIC) — 26KB
- f2.jpg (GRAPHIC) — 45KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-029012.txt ( ) — 277KB
- mnpr-20240912.xsd (EX-101.SCH) — 3KB
- mnpr-20240912_def.xml (EX-101.DEF) — 12KB
- mnpr-20240912_lab.xml (EX-101.LAB) — 15KB
- mnpr-20240912_pre.xml (EX-101.PRE) — 12KB
- mnpr20240911_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 12, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing positive early human clinical data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial validating MNPR-101-Zr's tumor targeting ability. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated September 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: September 12, 2024 By: /s/ Karthik Radhakrishnan Name: Karthik Radhakrishnan Title: Chief Financial Officer